Avipro Salmonella Duo

Indications

• Clinical term 1
• Common term 1
• Clinical term 2
• Common term 2

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Dose acts by modulating the activity of specific neurotransmitter receptors and ion channels, influencing various physiological pathways. Its precise mechanism may involve interactions with G-protein coupled receptors, leading to downstream signaling effects that impact cellular responses.

Pharmacodynamics

Dose exhibits a range of effects depending on the dosage and target tissues. It is known to alter neurotransmitter release, affect ion conductance, and influence metabolic pathways, thereby contributing to its therapeutic efficacy and potential side effects.

Pharmacokinetics

Dose is generally absorbed following administration, with peak plasma concentrations occurring within a specified timeframe. Its distribution is influenced by tissue binding and permeability across cell membranes. The drug is metabolized primarily in the liver, with metabolites being excreted via renal and biliary routes. The half-life can vary based on individual patient factors, including age, liver function, and other concurrent medications.

Indications

• Salmonella enterica infection
• Acute gastroenteritis
• Foodborne illness

Dosage

Children: Refer to specific antibiotic guidelines based on susceptibility and severity of infection.

Adults: Refer to specific antibiotic guidelines based on susceptibility and severity of infection.

Mechanism of action

Salmonella enterica invades the intestinal epithelial cells, leading to an inflammatory response. This invasion triggers the secretion of pro-inflammatory cytokines, which contribute to the symptoms of enteritis. The bacteria can also disrupt the tight junctions between epithelial cells, increasing intestinal permeability and leading to diarrhea.

Pharmacodynamics

The pharmacodynamics of managing enteriditis focuses on alleviating symptoms and preventing dehydration. Antimicrobial agents may be used in cases of severe infection or in high-risk patients. The effectiveness of treatment depends on the specific strain of Salmonella and its susceptibility to antibiotics. Supportive care, including fluid replacement, is crucial.

Pharmacokinetics

The pharmacokinetics of antibiotics used in treating enteriditis can vary widely. Generally, absorption occurs in the gastrointestinal tract, with peak plasma concentrations reached within hours after administration. The distribution in body fluids varies by drug, and metabolism primarily occurs in the liver, while excretion is mainly via the kidneys. Duration of action also varies based on the specific antibiotic chosen for treatment.

Adverse effects

• Diarrhea
• Fever
• Abdominal pain
• Nausea
• Vomiting
• Dehydration

Precautions

• Monitor hydration status, especially in pediatric and elderly patients.
• Consider the potential for antibiotic resistance if antibiotics are used.
• Assess for underlying gastrointestinal conditions.

Pregnancy

Safety during pregnancy has not been established; consult healthcare provider.

Breast-feeding

Consult healthcare provider as the safety of use during breastfeeding is not well studied.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Tuberculosis
• Leprosy
• Bacterial infections caused by susceptible organisms

Dosage

Children: Refer to BNF for Children for specific dosing.

Adults: Refer to prescribing guidelines for specific dosing.

Mechanism of action

Rif12 inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial DNA-dependent RNA polymerase. This interaction prevents transcription, thereby halting the production of essential proteins needed for bacterial growth and replication.

Pharmacodynamics

The pharmacodynamics of Rif12 is characterized by its bactericidal effect, which is particularly effective in the early phases of bacterial growth. The drug demonstrates concentration-dependent killing, meaning that higher concentrations result in more significant bacterial death. It has a post-antibiotic effect, allowing for continued bacterial suppression even after levels of the drug have fallen below the minimum inhibitory concentration.

Pharmacokinetics

Rif12 is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within a few hours after oral administration. It is extensively metabolized in the liver through oxidation and deacetylation, primarily mediated by cytochrome P450 enzymes. The elimination half-life varies but is generally around 3 to 5 hours. Rif12 is excreted mainly in the urine, with a small fraction eliminated in feces. It is important to note that the presence of food can affect its absorption.

Contra-indications

• Hypersensitivity to rifampicin or any component of the formulation
• Severe hepatic impairment
• Concurrent use with certain protease inhibitors

Adverse effects

• Hepatotoxicity
• Gastrointestinal disturbances (nausea, vomiting, diarrhea)
• Flu-like symptoms
• Rash
• Red-orange discoloration of bodily fluids
• Thrombocytopenia
• Liver enzyme elevations

Interactions

• Rifampicin is a potent inducer of cytochrome P450 enzymes, particularly CYP3A4, which can decrease the effectiveness of drugs metabolized by this pathway
• May reduce the effectiveness of oral contraceptives
• Increased metabolism of anticoagulants, leading to decreased anticoagulant effect
• Potential interactions with antiepileptic drugs, antidepressants, and other medications

Precautions

• Caution in patients with a history of liver disease
• Monitor liver function tests regularly during therapy
• Use with caution in patients taking other drugs that are hepatotoxic
• Patients should be informed about the possibility of body fluid discoloration

Pregnancy

Rifampicin is classified as Category C. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Rifampicin is excreted in breast milk. Caution should be exercised when administered to a nursing mother, and breastfeeding should be avoided if possible.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Capsules (150 mg, 300 mg)
• Oral suspension (100 mg/5 mL)
• Injectable solution (rifampicin for injection)

Indications

• Salmonellosis
• Gastroenteritis
• Typhoid fever
• Paratyphoid fever

Dosage

Children: Refer to appropriate guidelines based on the severity of the infection and local antimicrobial susceptibility patterns.

Adults: Refer to appropriate guidelines based on the severity of the infection and local antimicrobial susceptibility patterns.

Mechanism of action

Salmonella bacteria invade the intestinal mucosa and evade the host's immune response. They utilize a type III secretion system to inject virulence factors into host cells, facilitating their entry and promoting inflammation. This invasion disrupts normal intestinal function, leading to diarrhea, abdominal pain, and systemic symptoms.

Pharmacodynamics

The pathogenicity of Salmonella is largely attributed to its ability to adhere to and invade host epithelial cells, triggering an inflammatory response. The bacteria can survive and replicate within macrophages, allowing them to disseminate systemically. The inflammatory response contributes to the clinical manifestations of the infection, including fever and diarrhea.

Pharmacokinetics

Salmonella does not have pharmacokinetics as it is a bacterial pathogen rather than a drug. However, the course of infection can be influenced by host factors, such as immune response and the presence of underlying health conditions. Antibiotic treatment may alter the natural course of infection and influence the duration and severity of symptoms.

Adverse effects

• Diarrhea
• Fever
• Abdominal cramps
• Nausea
• Vomiting

Precautions

• Ensure proper food handling and hygiene practices to prevent infection.
• Use caution in immunocompromised patients who may be at higher risk for severe disease.

Pregnancy

Salmonella infections during pregnancy can lead to complications such as miscarriage or premature labor. Caution is advised.

Breast-feeding

Salmonella can be transmitted through contaminated breast milk, though this is rare. Mothers should be cautious about food hygiene.

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Salmonellosis
• Gastroenteritis
• Food poisoning

Dosage

Children: Refer to clinical guidelines for the management of Salmonella infections in children, which may include supportive care and antibiotic therapy tailored to the child's age and weight.

Adults: Refer to clinical guidelines for the management of Salmonella infections, including supportive care and antibiotic therapy when indicated.

Mechanism of action

Salmonella Typhimurium invades epithelial cells of the intestinal lining, using a type III secretion system to inject effector proteins that manipulate host cell functions. This invasion disrupts the host cell's cytoskeletal structure, allowing the bacteria to enter and replicate within the cells. The immune response to the infection can lead to inflammation and gastrointestinal symptoms.

Pharmacodynamics

The primary effect of Typhimurium infection is an inflammatory response in the gut, which results in diarrhea and abdominal pain. The severity of the disease can vary based on the individual's immune status and the infectious dose. The response to the bacteria involves both innate and adaptive immune mechanisms, which can lead to the clearance of the infection but may also cause complications in susceptible populations.

Pharmacokinetics

As a bacterium, Typhimurium does not have pharmacokinetic properties like traditional drugs. However, once ingested, it can survive and multiply in the gastrointestinal tract. The bacteria can then be detected in stool samples. The body responds by activating immune responses, which can include both local and systemic responses, but pharmacokinetics in the traditional sense does not apply.

Adverse effects

• Gastrointestinal disturbances
• Fever
• Abdominal pain
• Nausea
• Vomiting
• Dehydration

Precautions

• Use with caution in immunocompromised patients
• Consider hydration status in patients with gastrointestinal symptoms
• Monitor for antibiotic resistance in endemic areas

Pregnancy

No specific studies available, use only if clearly needed.

Breast-feeding

Limited data available, exercise caution and consider risks versus benefits.

Storage

Store in a cool, dry place away from direct sunlight.